Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of arglabin in preparation of drugs for Stargardt disease

A macular degeneration and application technology, applied in sensory diseases, drug combinations, pharmaceutical formulations, etc., to achieve the effects of high safety factor, high safety, and convenient administration methods

Inactive Publication Date: 2018-12-21
XIAMEN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far there is no report on the use of agaleb for Stargardt macular degeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of arglabin in preparation of drugs for Stargardt disease
  • Application of arglabin in preparation of drugs for Stargardt disease
  • Application of arglabin in preparation of drugs for Stargardt disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0029] Abca4 gene knockout mice are mostly used in the development of therapeutic drugs for STGD1. However, unlike STGD1 patients, in single-gene knockout mice, the degeneration of the retina is slow, and the more obvious pathological phenotypes generally appear after 8 months of age, which is not consistent with the phenotype of STGD1 juvenile onset. Therefore, in 2008 the laboratory of Krzysztof Palczewski reported the production of Abca4- / - R8 - / - Double-knockout mice have obvious STGD1 pathological changes such as shortening of the outer segment of photoreceptor cells, thinning of the outer nuclear layer, and accumulation of A2E at the age of 4 months, which can be used as an animal model of STGD1 disease. This embodiment adopts Abca4 - / - R8 - / - Double knockout mice were performed.

[0030] Agalabi was dissolved in DMSO to make 25ng / μL stock solution. Choose 2 months old Abca4 - / - R8 - / - Double-knockout mice, 6 mice were used as the agaleb treatment group, the mother...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of arglabin in the preparation of drugs for Stargardt disease, particularly type-I Stargardt disease. Arglabin plays the role of protecting not only retinal pigmentepithelia but also photoreceptor cells, and moreover, arglabin does not affect the functions of all the organs of the body and have no genetic toxicity, is highly safe, and is easy to administrate.

Description

technical field [0001] The invention relates to the technical field of medicines for Stargardt macular degeneration, in particular to the use of agaleb in the preparation of medicines for Stargardt macular degeneration. Background technique [0002] Stargardt macular degeneration is the most common hereditary macular degeneration of the retina, among which Stargardt disease type 1 (STGD1) is a type of early-onset autosomal recessive genetic eye disease caused by Abca4 gene mutation, which was first discovered in 1909 Reported by German ophthalmologist Karl Stargardt, its incidence rate is about 1 person in every 8000-10000 people, accounting for about 7% of macular degeneration diseases. More than 900 Abca4 mutations causing STGD1 have been reported so far, and the age of onset and severity of patients show great heterogeneity. Most patients with STGD1 develop the disease in juveniles or young adults, but some patients develop the disease after adulthood. It is generally be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61P27/02
CPCA61K31/365A61P27/02
Inventor 吴亚林廖怿
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com